Thomson Reuters Spotlights the Impact of Personalized Medicine on Pharmaceutical R&D
(Thomson Reuters ONE) -
New report details the potential advantages and challenges for the pharma
industry as it implements strategies for personalized medicine
PHILADELPHIA, PA, December 13, 2012 - The IP & Science business of Thomson
Reuters, the world's leading source of intelligent information for businesses
and professionals, today announced the publication of a new report that provides
a comprehensive view of the potential effects of personalized medicine on drug
research and development. Spotlight on Personalized Medicine, a Pharma Matters
report based on insights and information from Thomson Reuters Cortellis for
Competitive Intelligence and a selection of data from CMR International, details
the current challenges posed by the paradigm of stratified medicine as well as
its clinical, economic and societal value.
"An array of scientific and market factors have prompted the pharma industry to
question the sustainability of the current R&D model, which targets large
populations with chronic unmet medical needs," said Jon-Brett Harris, executive
vice president at Thomson Reuters. "Despite the commercial success of these
products, the one-size-fits-all focus has resulted in spiraling R&D costs,
longer development timelines and narrow product portfolios. New options,
specifically personalized medicine, appear to be an attractive and more
sustainable solution. This new report offers a detailed look into the possible
advantages and disadvantages of this potentially game-changing approach."
The report shows that a stratified paradigm could result in more efficient ways
of conducting drug development, as well as address increased public awareness
related to post-marketing withdrawals of popular drugs and debates concerning
drug pricing and reimbursement. Further, the ability to better assess biological
factors related to disease and therapy at the genetic level lends itself to the
development of safer, more effective treatments for specific patient subgroups.
The slow pace of the industry to adopt a more stratified approach has been
reinvigorated with high-profile drug launches and successes; however, numerous
challenges still exist that could affect a large-scale integration of the
personalized medicine paradigm into biopharmaceutical R&D. Analysis from Thomson
Reuters Cortellis for Competitive Intelligence suggests a gap in connecting the
dots between genetic variation, disease association, patient segments with those
variations, clinical trial design and patient recruitment in the clinic.
Thomson Reuters Cortellis, the premier life sciences platform, is the most
powerful tool of its kind for biopharmaceutical competitive intelligence, drug
pipeline, and drug research and development information. CMR International, a
Thomson Reuters business, is the world leader in global pharmaceutical R&D
performance measurement. To learn more about Cortellis and CMR International,
visit: http://ip-science.thomsonreuters.com/.
Click here to view Spotlight on Personalized Medicine.
Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial and risk, legal, tax and accounting, intellectual property and science
and media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs approximately 60,000 people and operates in over 100
countries. For more information, go to www.thomsonreuters.com.
CONTACT
Jen Breen
Thomson Reuters
Jennifer.breen(at)thomsonreuters.com
+1 215 823 1791
Abbey Anderson
Thomson Reuters
Abbey.anderson(at)thomsonreuters.com
+ 1 215 823 1894
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1664563]
Unternehmensinformation / Kurzprofil:
Datum: 13.12.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 212586
Anzahl Zeichen: 4858
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 129 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Spotlights the Impact of Personalized Medicine on Pharmaceutical R&D"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
